Accéder au contenu
Merck

Novel pleuromutilin derivatives as antibacterial agents: synthesis, biological evaluation and molecular docking studies.

Bioorganic & medicinal chemistry letters (2012-08-31)
Xinyang Wang, Yong Ling, Hui Wang, Jianghe Yu, Junming Tang, Heng Zheng, Xi Zhao, Donggeng Wang, Guangtong Chen, Wenqian Qiu, Jinhua Tao
RÉSUMÉ

Owing to the increasingly serious problems caused by multidrug resistance in community-acquired infection pathogens, it has become an urgent need to develop new classes of antibiotics for overcoming the resistance. In this paper, we describe the design and synthesis of novel pleuromutilin derivatives containing the (2-aminothiazol-4-yl)-4-methyl group, as well as their in vitro antibacterial activities against Gram-positive clinical bacteria. Most of the tested compounds displayed strong antibacterial activities against these methicillin-susceptible and methicillin-resistant bacteria. Particularly noteworthy compound 15 and its derivative 16e, both showed potent antibacterial properties (0.0625-0.5μg/mL) that are superior to amoxicillin and tiamulin. Molecular docking studies suggested that the amino thiazole ring on the side chains of the pleuromutilin derivatives can in general be accommodated near the mutilin core in the binding pocket, and thus play an important role in the activity of the whole molecule. The findings reported herein may provide a new insight into the design of novel pleuromutilin derivatives for human clinical use.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Pleuromutilin, ≥95%